MicroRNA regulator of the clinical form of endocrine ophthalmopathy

Abstract

Endocrine ophthalmopathy is an extrathyroidal lesion of Graves’ disease, the pathogenesis of which is not fully understood. The clinical picture of this lesion is polyvariant, which creates difficulties in determining individual treatment; there are no clear criteria for assessing the effectiveness of the therapy. The causes of glucocorticoid resistance in patients with endocrine ophthalmopathy remain controversial to this day. The development of epigenetics has brought a lot of new information both to the understanding of the development of the pathogenesis of this disease, the formation of its clinical forms, and to the understanding of the causes of a negative response to glucocorticoid therapy, which has remained the gold standard in treatment for 67 years. MicroRNAs, which have attracted the attention of researchers in the last two decades, are necessary for the normal development of various physiological systems of the body; changes in their expression are associated with the development of many human diseases, including autoimmune diseases, which include endocrine ophthalmopathy.